Progressive Care Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 9 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2011 12 months to Dec 31, 2011
Cash flows from operating activities:
Net loss from continuing operations
Loss from discontinued operations - net of tax
Net (loss) income attributable to Common Shareholders
Depreciation
Change in provision for doubtful accounts
Net Income (Loss) Attributable to Parent

Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation
Gain on disposition of subsidiary - discontinued operations
Forgiveness of accrued interest - former related party
Change in provision for credit losses
Stock-based compensation
Recognition of stock-based compensation - related parties
Contributed services - related party
Amortization of debt issuance costs and debt discounts
Gain on debt extinguishment
Series A Preferred Stock dividend associated with induced conversion
Debt conversion expense
Other financing costs
Day one loss on issuance of units
Day one loss on debt modification
Amortization of right-of-use assets - finance leases
Amortization of right-of-use assets - operating leases
Change in accrued interest on lease liabilities
Change in fair value of derivative liability
Change in accrued interest on notes payable
Amortization of intangible assets
Amortization of debt issuance cost
Gain on sale or disposal of property and equipment
Goodwill impairment
Accounts receivable
Grant receivable
Inventory
Prepaid expenses
Deposits
Accounts payable and accrued liabilities
Deferred rent
Income tax payable
Accrued interest payable - related parties
Operating lease liabilities
Net cash provided by operating activities

Cash flows from investing activities:
Cash acquired in acquisition of PharmCo less cash disposed of in sale of subsidiary
Purchase of property and equipment
Discontinued operations
Proceeds from disposal of fixed assets
Proceeds from sale or disposal of property and equipment
Purchase of intangible assets
Net cash used in investing activities

Cash flows from financing activities:
Cash overdraft
Proceeds from issuance of notes payable
Gross proceeds from issuance of preferred stock
Proceeds from warrants exercised
Proceeds from issuance of preferred stock allocated to derivative liabilities
Payment of stock issuance costs
Payment of debt discount and debt issuance costs
Payments on notes payable
Repayment of note payable - related party
Payments on finance lease liabilities
Issuance of common stock for PIPE transaction
Net cash provided by financing activities

Net increase (decrease) in cash
Cash at beginning of year/period
Cash at end of year/period
Increase in cash
Cash at beginning of period
Cash at end of period
Supplemental disclosures of cash flow information:
Cash paid for taxes
Cash paid for interest
Cash paid for income taxes

Debt extension fees and other financing costs added to note principal
Supplemental schedule of non-cash investing and financing activities:
Issuance of common stock in connection with Pharmco acquisition
Issuance of common stock in connection with the conversions of debt and accrued interest
Issuance of warrants as debt issue cost
Business combination without transfer of consideration
Debt conversion of long-term notes payable and accrued interest, net of unamortized debt discount and debt issuance costs
Issuance of common stock and common stock purchase warrants for debt conversion
Debt extension fees and other financing costs added to note principal
Issuance of common stock for services rendered
Insurance premiums financed through issuance of note payable
Equipment purchase financed through issuance of note payable

Comments